Company intelligence
Eugia US LLC
Experience the Eugia Difference
About Eugia US LLC
Eugia is an independent specialty pharmaceutical company focused on delivering generic sterile injectables, oncology, hormones, and ophthalmic medicines. Our best-in-class, dedicated manufacturing and R&D capabilities are poised to meet today’s customer needs, and we are committed to providing our customers and partners with high-quality specialty medicines. Our name embodies who we aspire to be as a company – EU meaning “good” and hyGIA being the goddess of good health – together reflecting our focus on delivering products that are foundational to ensuring good health for millions of people around the world. For more information, visit EugiaUS.com
Verified activity
Signals from Eugia US LLC
6 published signals
Research & Knowledge
Eugia US LLC reported that secondary endpoints for the Skyline program included clinical remission by modified Mayo Score of 20% and endoscopic improvement of 30%.
Reported by Donald DeWitt
Research & Knowledge
Eugia US LLC reported that SPY003 induced a 10-point reduction from baseline in Robarts Histopathology Index (RHI) score by Week 12 for patients with moderately-to-severely active UC.
Reported by Donald DeWitt
Research & Knowledge
Eugia US LLC described the Skyline program as a two-part induction and maintenance platform trial for moderately-to-severely active UC patients consisting of three investigational antibodies: SPY001, SPY002, and SPY003.
Reported by Donald DeWitt
Research & Knowledge
Eugia US LLC published results from a trial where 393 patients received a median of three prior lines of therapy and had a 74% objective response rate for etentamig compared to 45.7% for standard available therapies after a median follow-up of 11.4 months.
Reported by Donald DeWitt
Research & Knowledge
Eugia US LLC published a longitudinal study comparing semaglutide treatment to matched calorie restriction in direct comparison to preserve baseline function and recapitulate functional benefits.
Reported by Donald DeWitt
Research & Knowledge
Eugia US LLC published a study finding that 30 percent of study participants had lung cancer cells shrink.
Reported by Donald DeWitt